Bevacizumab

Generic Name: Bevacizumab

Brand Names: Avastin, Mvasi, Oyavas, Alymsys, Aybintio, Abevmy, Vegzelma, Onbevzi, Zirabev, Lytenava, Avzivi

Drug Type: Biotech

Chemical Formula: -

CAS Number: 216974-75-3

Unique Ingredient Identifier: 2S9ZZM9Q9V

Background: There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells. VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target for anti-cancer therapies.
...

Indication: As a vascular endothelial growth factor (VEGF) inhibitor, bevacizumab is used in several chemotherapy regimens to treat metastatic colorectal cancer; metastatic, unresectable, locally advanced or recurrent non-squamous non-small cell lung cancer; metastatic renal cell carcinoma; metastatic, persistent, or recurrent cervical cancer; primary peritoneal cancer;...

Associated Conditions: Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Colorectal Cancer (CRC), Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Persistent Cervical Cancer, Recurrent Cervical Cancer, Recurrent Glioblastoma, Relapsed Glioblastoma, Stage III Fallopian Tube Cancer, Stage III Ovarian Epithelial Cancer, Stage III Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent Non-Squamous Non-Small Cell Lung Cancer, Recurrent Platinum-Sensitive Epithelial Ovarian Cancer, Recurrent Platinum-resistant Epithelial Ovarian Cancer, Recurrent platinum drug resistant Fallopian tube cancer, Recurrent platinum drug resistant primary peritoneal cancer, Recurrent platinum sensitive primary peritoneal cancer, Recurrent platinum-sensitive fallopian tube cancer, Unresectable Non-Squamous Non-Small Cell Lung Cancer, Unresectable, advanced Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

Associated Therapies: First Line Chemotherapy, First or Second Line Therapy, Second Line Treatment

Clinical Trials

Multicenter Evaluation of Docetaxel, Gemcitabine, and Bevacizumab Combination Followed by Bevacizumab Alone in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: docetaxel
Drug: gemcitabine
Drug: bevacizumab

First Posted Date: 2006-09-20

Last Posted Date: 2010-01-26

Lead Sponsor: Sanofi

Target Recruit Count: 17

Registration Number: NCT00378573

Locations: 🇺🇸
Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States

Phase II Study of Bevacizumab, Capecitabine and Oxaliplatin in Colon Cancer

Phase 2

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Bevacizumab

First Posted Date: 2006-09-19

Last Posted Date: 2013-01-23

Lead Sponsor: Asan Medical Center

Target Recruit Count: 49

Registration Number: NCT00378066

Locations: 🇰🇷
Yonsei University Hospital, Seoul, Korea, Republic of
🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

and more 3 locations

Combination Therapy for Age-Related Macular Degeneration.

Phase 2

Completed

Conditions: Age Related Macular Degeneration

Interventions: Drug: Avastin (Bevacizumab)
Drug: Bevacizumab

First Posted Date: 2006-09-15

Last Posted Date: 2011-09-28

Lead Sponsor: Lawson Health Research Institute

Target Recruit Count: 103

Registration Number: NCT00376701

Locations: 🇨🇦
The University of British Columbia, Vancouver, British Columbia, Canada
🇨🇦
The University of Alberta and Capital Health, Edmonton, Alberta, Canada
🇨🇦
Dr. Stanley G. Shortt, Victoria, British Columbia, Canada

and more 2 locations

A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer

Phase 3

Completed

Conditions: Breast Neoplasms

Interventions: Drug: Sunitinib
Drug: bevacizumab
Drug: paclitaxel

First Posted Date: 2006-09-08

Last Posted Date: 2012-09-10

Lead Sponsor: Pfizer

Target Recruit Count: 488

Registration Number: NCT00373256

Locations: 🇪🇸
Pfizer Investigational Site, Madrid, Spain

Effect of Intravitreal Bevacizumab on Clinically Significant Macular Edema

Phase 3

Conditions: Diabetic Macular Edema

First Posted Date: 2006-09-01

Last Posted Date: 2007-02-22

Lead Sponsor: Shahid Beheshti University of Medical Sciences

Target Recruit Count: 150

Registration Number: NCT00370669

Locations: 🇮🇷
Masoud Soheilian, Tehran, Iran, Islamic Republic of

Effect of Intravitreal Bevacizumab on Non -Age-Related Macular Degeneration (AMD) Related Choroidal Neovascularization (CNV)

Phase 3

Completed

Conditions: Choroidal Neovascularization

Interventions: Drug: bevacizumab

First Posted Date: 2006-09-01

Last Posted Date: 2008-07-11

Lead Sponsor: Shahid Beheshti University of Medical Sciences

Target Recruit Count: 31

Registration Number: NCT00370786

Locations: 🇮🇷
Hamid Ahmadieh, MD, Tehran, Iran, Islamic Republic of

Intravitreal Bevacizumab for Management of Active Progressive Proliferative Diabetic Retinopathy (PDR)

Phase 3

Conditions: Diabetic Retinopathy

Interventions: Drug: bevacizumab

First Posted Date: 2006-09-01

Last Posted Date: 2008-06-26

Lead Sponsor: Shahid Beheshti University of Medical Sciences

Registration Number: NCT00370721

Locations: 🇮🇷
Hamid Ahmadieh, MD, Tehran, Iran, Islamic Republic of

Intravitreal Bevacizumab vs. Bevacizumab Combined With Triamcinolone for Neovascular AMD

Phase 3

Conditions: Neovascular Age-Related Macular Degeneration

Interventions: Drug: bevacizumab + triamcinolone acetonide
Drug: bevacizumab

First Posted Date: 2006-08-31

Last Posted Date: 2008-06-26

Lead Sponsor: Shahid Beheshti University of Medical Sciences

Registration Number: NCT00370370

Locations: 🇮🇷
Hamid Ahmadieh, MD, Tehran, Iran, Islamic Republic of

A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer

Phase 2

Completed

Conditions: Thymic Cancer
Thymoma

First Posted Date: 2006-08-30

Last Posted Date: 2014-06-03

Lead Sponsor: Indiana University School of Medicine

Target Recruit Count: 18

Registration Number: NCT00369889

Locations: 🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States

Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: Erlotinib
Drug: Bevacizumab

First Posted Date: 2006-08-23

Last Posted Date: 2016-02-11

Lead Sponsor: Nasser Hanna, M.D.

Target Recruit Count: 25

Registration Number: NCT00367601

Locations: 🇺🇸
Medical & Surgical Specialists, LLC, Galesburg, Illinois, United States
🇺🇸
Community Regional Cancer Center, Indianapolis, Indiana, United States
🇺🇸
Cancer Care Center of Southern Indiana, Bloomington, Indiana, United States

and more 10 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy